Cold War tensions and the polio vaccine was the first polio vaccine to receive approval of the U.S. government, and was used until 1961 in America, when the Sabin vaccine was recommended to replace it. Albert Sabin, a virologist who publicly disagreed with Salk and his killed vaccine, worked on creating a vaccine with live, attenuated vaccines. Despite Cold War tensions, in January, 1956 Mikhail Chumakov, the director of Moscow's Polio Research Institute, his wife and colleague Marina Voroshilova, and Anatoli Smorodentsev, traveled to the U.S. in order to study the Salk vaccine and visited the laboratory of Albert Sabin. With the clearance of the FBI, Sabin
Polio vaccine attenuate the Sabin 2 strain, and 10 substitutions are involved in attenuating the Sabin 3 strain. The primary attenuating factor common to all three Sabin vaccines is a mutation located in the virus's internal ribosome entry site, which alters stem-loop structures, and reduces the ability of poliovirus to translate its RNA template within the host cell. The attenuated poliovirus in the Sabin vaccine replicates very efficiently in the gut, the primary site of infection and replication, but is unable to replicate efficiently within nervous system tissue. In 1961, type 1 and 2 monovalent oral poliovirus vaccine (MOPV) was licensed, and